This finding further supports the notion that activation of the MAPK/ERK1,2 signalling pathway had no impact on mROS generation in HSVSMCs from either non-diabetic or T2DM patients, similar to the results with Ang II. This evidence concerns the gene MAPK3 and type 2 diabetes mellitus.